Colony-Stimulating Factors
-
Subject Areas on Research
-
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
-
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
-
5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway.
-
A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.
-
A cost analysis of hematopoietic colony-stimulating factors.
-
A distinct wave of human T cell receptor gamma/delta lymphocytes in the early fetal thymus: evidence for controlled gene rearrangement and cytokine production.
-
A predictive model for neutropenia associated with cancer chemotherapy.
-
A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.
-
Antithymocyte globulin stimulates human hematopoietic progenitor cells.
-
Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.
-
Balancing the benefits and costs of colony-stimulating factors: a current perspective.
-
Biosimilars: are they ready for primetime in the United States?
-
Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.
-
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
-
Clinical implications for the administration of colony stimulating factors.
-
Colony stimulating factors for chemotherapy induced febrile neutropenia.
-
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
-
Colony-stimulating factors: clinical applications.
-
Conditions for an in vitro culture of murine mixed hematopoietic colonies and their putative cellular origin.
-
Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.
-
Deletion of carboxy-terminal residues of murine granulocyte-macrophage colony-stimulating factor results in a loss of biologic activity and altered glycosylation.
-
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
-
Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.
-
Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
-
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
-
Effects of hematopoietic growth factors following myeloablation in a primate model.
-
Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
-
Evidence-based use of colony-stimulating factors in elderly cancer patients.
-
Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines.
-
Granulocyte colony-stimulating factors: finding the right indication.
-
Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells.
-
Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors.
-
Granulocyte-macrophage colony-stimulating factor primes neutrophils by activating a pertussis toxin-sensitive G protein not associated with phosphatidylinositol turnover.
-
Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
-
Hematopoietic growth factors in the older cancer patient.
-
Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
-
High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates.
-
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
-
Human thymic epithelial cells produce granulocyte and macrophage colony-stimulating factors.
-
Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis.
-
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
-
Introduction. Neutropenia risk models in oncology.
-
Macrophages Contribute to the Spermatogonial Niche in the Adult Testis.
-
Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.
-
Myeloid growth factors clinical practice guidelines in oncology.
-
Myeloid growth factors.
-
Myeloid growth factors.
-
Myeloid growth factors. Clinical practice guidelines in oncology.
-
Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans.
-
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
-
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
-
Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.
-
Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.
-
Reculturing of cells from primary CFU-C colonies.
-
Renal epithelial cell-derived monocyte colony stimulating factor as a local informant of renal injury and means of monocyte activation.
-
Risk assessment in oncology clinical practice. From risk factors to risk models.
-
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
-
Risks and consequences of chemotherapy-induced neutropenia.
-
Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
-
Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
-
Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
-
Supportive care of the marrow transplant recipient: the Seattle Experience.
-
The colony-stimulating factors: use to prevent and treat neutropenia and its complications.
-
The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
-
The myeloid growth factors.
-
The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation.
-
Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?
-
Two different types of granulocyte colony-stimulating factor produced by bovine lung tissue.
-
Tyrosine phosphorylation in human neutrophil.
-
Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.
-
Update of the economic analyses of the use of the colony-stimulating factors.
-
Update on neutropenia and myeloid growth factors.
-
Use of re-randomized data in meta-analysis.
-
Keywords of People